Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases

In Vivo

Volumn 16, Issue 6, 2002, Pages 451-457

  Datta, Anjuli ^a   Kitson, Richard P ^a   Xue, Yaming ^a   Al Atrash, Gheath ^a   Mazar, Andrew P ^b,c   Jones, Terence R ^b   Goldfarb, Ronald H ^d  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b Angstrom Pharmaceuticals   (United States)

^c Attenuon LLC   (United States)

^d Sopherion Therapeutics Inc   (United States)

Author keywords

Chemo anti angiogenic therapy; Metastasis; uPA uPAR

Indexed keywords

A 6; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; MATRIGEL; OCTAPEPTIDE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; MESSENGER RNA; PEPTIDE FRAGMENT; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG BURDEN; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; DRUG COMBINATION; DRUG EFFECT; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036862402     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Goldfrab RH and Liotta LA: Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 12: 294-307, 1986.
2. Fidler IJ, Gersten DM, Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res 28: 149-250, 1978.
3. Heppner GH: Tumor heterogeneity. Cancer Res 44: 2259-65, 1984.
4. Goldfarb RH and Brunson KW: Overview of current understanding of tumor spread. In: Fundamental Aspects of Cancer, vol. 1, Cancer Growth and Progression (Goldfarb RH, ed.) Dordrecht, Kluwer, 1989, pp 28-32.
5. Mazar AP, Gawlak S, Goldfarb RH, Kitson RP, Rabbani SA, Guo Y, Gown AM and Jones TR: The urokinase plasminogen activator receptor (uPAR) is a chokepoint for carcinoma metastasis and angiogenesis. Recent Res Devel Cancer 2: 1-12, 2000.
6. Kristensen P, Eriksen J, Blasi F and Dano K: Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 115: 1763-71, 1991.
7. Mazar AP, Henkin J and Goldfarb RH: The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15-32, 1999.
8. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S and Mignatti P: Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J 16: 2319-32, 1997.
9. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V and Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629-4636, 1981.
10. Mulligan-Kehoe MJ, Wagner R, Wieland C and Powell R: A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product. J Biol Chem 276: 8588-96., 2001.
11. Stahl A and Mueller BM: Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54: 3066-71, 1994.
12. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K and Brunner N: Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 91: 869-74, 1999.
13. Goldfarb RH, Ziche M, Murano G and Liotta LA: Plasminogen activators (urokinase) mediate neovascularization: Possible role in tumor angiogenesis. Semin Thromb Hemost 12: 337-8, 1986.
14. Folkman J and Haudenschild C: Angiogenesis in vitro. Nature 288: 551-6, 1980.
15. Gamble JR, Matthias U, Meyer G, Kaur P, Russ G, Faull R, Berndt MC and Vadas MA: Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 121: 931-43, 1993.
16. Haralabopoulos GC, Grant IDS, Kleinman HK, Lelkes PI, Papaioannou SP and Maragoudakis ME: Inhibitors of basement membrane collagen synthesis prevent endothelial cell alignment in Matrigel in vitro and angiogensis in vivo. Lab Invest 71: 575-82, 1994.
17. Thompson WD, Li WW and Maragoudakis M: The clinical manipulation of angiogenesis: Pathology, side-effects, surprises, and opportunities with novel human therapies. J Pathol 190: 330-7, 2000.
18. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 31528, 1994.
19. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP and Kalluri R: Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275: 1209-15, 2000.
20. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton TJ, Shuman MA and Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56: 2428-33, 1996.
21. Brower V: Tumor angiogenesis - New drugs on the block. Nat Biotechnol 17: 963-8, 1999.
22. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP and Rabbani SA: A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14: 1400-10, 2000.
23. Mishima K, Mazar AP, Gown A, Skelly M, Ji XD, Wang XD, Jones TR, Cavenee WK and Huang HJ: A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 97: 8484-9, 2000.
24. Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM and Appelt K: Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies. Clin Cancer Res 5: 1905-17, 1999.
25. O'Connell KA and Edidin M: A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J Immunol 144: 521-5, 1990.
26. Roche PC, Campeau JD and Shaw ST Jr.: Comparative electrophoretic analysis of human and porcine plasminogen activators in SDS-polyacrylamide gels containing plasminogen and casein. Biochim Biophys Acta 745: 82-9, 1983.
27. Goldfarb RH: Plasminogen activators. Annual Reports in Medicinal Chemistry 18: 257-264, 1983.
28. Skriver L, Larsson LI, Kielberg V, Nielsen LS, Andresen PB, Kristensen P and Dano K: Immunocytochernical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 99: 752-7, 1984,
29. Plum SM, Hanson A, Volker KM, Sim BKL, Fogler WE and Fortier AH: Synergistic effects of recombinant human endostatin in combination with Adriamycin on in vitro endothelial cell activity as well as tumor growth in vivo. Proc Am Assoc Cancer Res 42: 580, 2001.
30. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-86, 2000.